Milestone Asset Management LLC Grows Position in IQVIA Holdings Inc. (NYSE:IQV)

Milestone Asset Management LLC boosted its position in IQVIA Holdings Inc. (NYSE:IQV) by 11.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,998 shares of the medical research company’s stock after purchasing an additional 204 shares during the period. Milestone Asset Management LLC’s holdings in IQVIA were worth $393,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of the business. Capital Performance Advisors LLP bought a new stake in shares of IQVIA during the 3rd quarter worth approximately $27,000. Park Place Capital Corp purchased a new stake in IQVIA in the third quarter worth $28,000. Avior Wealth Management LLC lifted its position in shares of IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after purchasing an additional 87 shares during the last quarter. Assetmark Inc. grew its holdings in shares of IQVIA by 612.5% in the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after purchasing an additional 196 shares during the last quarter. Finally, UMB Bank n.a. increased its stake in IQVIA by 74.4% in the 3rd quarter. UMB Bank n.a. now owns 232 shares of the medical research company’s stock worth $55,000 after buying an additional 99 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

Shares of IQV opened at $201.42 on Friday. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73. The stock has a fifty day moving average price of $200.34 and a 200-day moving average price of $220.78. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. The firm has a market cap of $36.56 billion, a PE ratio of 26.43, a P/E/G ratio of 2.14 and a beta of 1.48.

Analyst Upgrades and Downgrades

A number of brokerages have commented on IQV. Barclays dropped their target price on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Stephens assumed coverage on IQVIA in a report on Friday, December 20th. They set an “overweight” rating and a $250.00 price objective on the stock. Evercore ISI lowered their target price on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Leerink Partners restated an “outperform” rating and set a $248.00 price target (down previously from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Finally, Deutsche Bank Aktiengesellschaft lowered their price objective on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Four analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $255.71.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.